CD274 and renal cell carcinoma: Several early phase clinical trials are currently underway to evaluate the safety and efficacy of TIGIT inhibitors, in combination with an anti-PD-1/PD-L1, for the treatment of metastatic tumors, including RCC (NCT03977467, NCT02913313, NCT04626479).